Amphastar Pharmaceuticals, Inc.
HealthcareNASDAQ:AMPH · NASDAQ Global Select
-$0.44 today
Vol 0.38M · Avg 0.59M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
12.4%
avg 9.3%
ROIC
7.5%
avg 5.1%
ROA
6.0%
avg 5.2%
Analysis
ROE is currently the strongest return metric at 12.4% versus its period average of 9.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Yongfeng Zhang | Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Director | $1.71M | — | 79 | $2.99M | 6.78% |
Ziping Luo | Chairman of the Board, Chief Scientist & Chief Operating Officer | $1.25M | — | 76 | $1.10M | 2.50% |
William J. Peters | Chief Financial Officer, Executive Vice President of Finance, Treasurer & Director | $1.15M | — | 58 | $175,063.00 | 0.40% |
Rong Zhou | Senior EVice President of Production & EVP of Scientific Affairs | $1.14M | — | 67 | $171,554.00 | 0.39% |
Jacob Liawatidewi | Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director | $853,851.00 | — | 52 | $121,892.00 | 0.28% |
Tony Marrs | Executive Vice President of Regulatory Affairs & Clinical Operations | — | — | — | — | — |
Dan Dischner | Senior Vice President of Human Resources & Corporate Communication | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$982,854.53
Net Sentiment
$982,854.53
Net selling
Most Active
Petersen Floyd F.
8 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 10 sells worth $982,854.53 over the last 12 months. That adds up to net selling of $982,854.53. Petersen Floyd F. was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +7.2% | +8.4% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +7.2% over three years. Forward estimates point to Revenue at +8.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Dynavax Technologies Corporation
DVAX
$1.82B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.62B
Harrow Health, Inc.
NASDAQ:HROW
$1.40B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
$1.12B
CureVac N.V.
CVAC
$1.05B
Pacira BioSciences, Inc.
NASDAQ:PCRX
$904.31M
Beta Bionics, Inc.
NASDAQ:BBNX
$647.48M
Embecta Corp.
NASDAQ:EMBC
$183.92M
Who manages AMPH?
Amphastar Pharmaceuticals, Inc. (AMPH) lists 7 active executives. The top listed executive is Jacob Liawatidewi, Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director.
Are AMPH insiders buying or selling?
Recent insider activity shows net buying of $1.77M.
Explore More
Continue the stock analysis
Jump to another research area for this company.